Between Partnership and Risk: Localizing and Securitizing Narratives about China in Fijian News Media, 2022–2025
Media and Communication Research · 2026 · 7 (2)
DOI: 10.23977/mediacr.2026.070202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Media and Communication Research, 2026.
Abstract (Originalsprache)
: This article investigates how three Fijian English-language news outlets made sense of China-related issues during a period of intensified Pacific regional debate from 2022 to 2025. Drawing on a cleaned corpus of 178 articles from FBC News, The Fiji Times, and Fiji Sun, and a close qualitative reading of 75 theoretically rich texts, it argues that Fijian media do not simply reproduce external narratives. Instead, China-related coverage is shaped by issue-conditioned narrative mediation. Development, health, agriculture, climate, and infrastructure stories are commonly localized into partnership narratives when attached to concrete Fijian and Pacific needs. By contrast, policing, defence, military-base concerns, PIF/Chinese Taiwan disputes, influence-related reporting, and infrastructure accountability are more likely to be securitized or risk-framed. Across both processes, Pacific agency matters. Fijian and regional actors use sovereignty, consensus, balanced diplomacy, the Ocean of Peace, and regional priorities to filter external frames.
Zitieren
APA
(2026). Between Partnership and Risk: Localizing and Securitizing Narratives about China in Fijian News Media, 2022–2025. Media and Communication Research, 7(2). https://doi.org/10.23977/mediacr.2026.070202
Vancouver
Between Partnership and Risk: Localizing and Securitizing Narratives about China in Fijian News Media, 2022–2025. Media and Communication Research. 2026;7(2). doi:10.23977/mediacr.2026.070202
BibTeX
@article{euvimed2026,
title = {Between Partnership and Risk: Localizing and Securitizing Narratives about China in Fijian News Media, 2022–2025},
journal = {Media and Communication Research},
year = {2026},
volume = {7},
number = {2},
doi = {10.23977/mediacr.2026.070202}
}
EUVIMED